Last reviewed · How we verify
TT-01488 Tablets
At a glance
| Generic name | TT-01488 Tablets |
|---|---|
| Sponsor | TransThera Sciences (Nanjing), Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies (PHASE1)
- Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TT-01488 Tablets CI brief — competitive landscape report
- TT-01488 Tablets updates RSS · CI watch RSS
- TransThera Sciences (Nanjing), Inc. portfolio CI